Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine the maximum tolerated dose of alloreactive NK cells that can be transfused following stem cell transplant.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Indiana University School of Medicine
NCT06303193 · Myelodysplastic Syndromes
NCT06847867 · Myelodysplastic Syndromes
NCT06439199 · Acute Myeloid Leukemia, Myelodysplastic Syndromes, and more
NCT07216443 · Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, and more
NCT06656494 · Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
Indiana University Cancer Center
Indianapolis, Indiana
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions